If you happen to see a question you know the answer to, please do chime in and help your fellow community members. We encourage our fourm members to be more involved, jump in and help out your fellow researchers with their questions. GATK forum is a community forum and helping each other with using GATK tools and research is the cornerstone of our success as a genomics research community.We appreciate your help!
Test-drive the GATK tools and Best Practices pipelines on Terra
Check out this blog post to learn how you can get started with GATK and try out the pipelines in preconfigured workspaces (with a user-friendly interface!) without having to install anything.
PGT and PID is a dot
I am following the best practice pipeline with version 3.6 of gatk and in order to reduce the amount of compound heteozygote variants found in my analysis, I recently chose to "mature" into using the phased gt annotations PID and PGT and I have very nice results.
However I found a high amount of variants with a dot ('.') in both fields in the vcfs I started to use the new analysis on.
I scanned around in the forums and documentation, however I could not find any sign what that means.
this is especially interesting, as I have several variants where the variants are on the same read only, however only a few of the variants are phased, the others show the '.'
I am pleased the with the outcome already however I fear that I might miss information.
I included the screenshot as well as an overview of the variants in that region.
I would appreciate it if you could shed some light on this issue, even if it is just " the dot means we were not sure about it"
chr1 152280671 . A C 3783.47 VQSRTrancheSNP99.90to100.00 AC=1;AF=0.019;AN=2;BaseQRankSum=5.09;ClippingRankSum=0;DP=26522;ExcessHet=10.4471;FS=22.852;InbreedingCoeff=-0.0643;MLEAC=7;MLEAF=0.019;MQ=58.86;MQRankSum=-7.267;QD=1.96;ReadPosRankSum=-1.448;SOR=2.749;VQSLOD=-14.1;culprit=MQRankSum GT:AD:DP:GQ:PGT:PID:PL 0/1:277,34:311:99:0|1:152280669_T_C:585,0,11704 chr1 152280685 . C A 9358.84 VQSRTrancheSNP99.90to100.00 AC=1;AF=0.019;AN=2;BaseQRankSum=4.79;ClippingRankSum=0;DP=35550;ExcessHet=33.4707;FS=9.592;InbreedingCoeff=-0.1314;MLEAC=11;MLEAF=0.03;MQ=58.82;MQRankSum=-7.86;QD=3.99;ReadPosRankSum=-2.019;SOR=1.604;VQSLOD=-8.457;culprit=MQRankSum GT:AD:DP:GQ:PGT:PID:PL 0/1:299,66:365:99:0|1:152280669_T_C:1871,0,12440 chr1 152280687 . C T 9105.01 VQSRTrancheSNP99.90to100.00 AC=1;AF=0.019;AN=2;BaseQRankSum=5.67;ClippingRankSum=0;DP=35912;ExcessHet=38.6724;FS=9.592;InbreedingCoeff=-0.1438;MLEAC=12;MLEAF=0.033;MQ=58.81;MQRankSum=-7.86;QD=3.89;ReadPosRankSum=-1.766;SOR=1.605;VQSLOD=-8.451;culprit=MQRankSum GT:AD:DP:GQ:PGT:PID:PL 0/1:299,66:365:99:0|1:152280669_T_C:1840,0,13062 chr1 152280688 . A G 9486.72 VQSRTrancheSNP99.90to100.00 AC=1;AF=0.019;AN=2;BaseQRankSum=9.54;ClippingRankSum=0;DP=36233;ExcessHet=39.4426;FS=9.592;InbreedingCoeff=-0.1455;MLEAC=8;MLEAF=0.022;MQ=58.83;MQRankSum=-7.765;QD=4.02;ReadPosRankSum=-1.182;SOR=1.63;VQSLOD=-8.617;culprit=MQRankSum GT:AD:DP:GQ:PGT:PID:PL 0/1:303,66:371:99:.:.:1926,0,13029 chr1 152280691 . A T 11612.7 VQSRTrancheSNP99.90to100.00 AC=1;AF=0.025;AN=2;BaseQRankSum=6.18;ClippingRankSum=0;DP=38167;ExcessHet=38.2356;FS=4.867;InbreedingCoeff=-0.1452;MLEAC=13;MLEAF=0.036;MQ=58.89;MQRankSum=-10.18;QD=3.99;ReadPosRankSum=-1.247;SOR=1.173;VQSLOD=-9.026;culprit=MQRankSum GT:AD:DP:GQ:PGT:PID:PL 0/1:281,110:391:99:.:.:3611,0,11146